Pharmaceutical News

RSS

Supreme Court sides with generic drug makers

The Supreme Court ruled on Monday that generic drugmakers cannot be sued under state law for adverse reactions to their products, a decision that consumer advocates called a blow to patient safety. In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, owned by Sun Pharmaceutical Industries Ltd, overturning a multimillion-dollar jury award to a badly injured patient in New Hampshire who alleged a generic drug she had taken was unsafe based on its chemical design (Hurley and Berkrot, 6/24).

26 Jun 2013

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

When you take a medicine you may want the drug to all be released immediately or perhaps more slowly over a longer period of time. If we can make a medicine where we control the release then we can tailor our medicines to release at the exact rate we choose that is best for the patient.

26 Jun 2013

Report alerts clinicians, public about catastrophic dangers of contaminated epidural injections

Investigators from the Centers for Disease Control and Prevention describe pathologic findings from 40 case reports of fungal infection in patients who had been given contaminated epidural, paraspinal, or intra-articular (into joints) steroid injections and correlate these findings with clinical and laboratory data.

26 Jun 2013

Study explores analgesic activity of ceftriaxone in humans

A single dose of the antibiotic ceftriaxone given for antimicrobial prophylaxis prior to surgery enhanced patient pain thresholds after the procedure, according to a study published in The Journal of Pain, the peer review publication of the American Pain Society.

26 Jun 2013

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio AB announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs.

26 Jun 2013

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

For treating the estimated 100 million Americans with chronic pain -- a population larger than those with heart disease, cancer and diabetes combined -- researched reported in The Journal of Pain shows that primary care physicians overwhelmingly prefer to prescribe non-steroidal anti-inflammatory medications, in accordance with published clinical practice guidelines.

26 Jun 2013

Researchers discover promising new way to treat HIV-related blood cancer

Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

26 Jun 2013

Vitamin D supplements lower blood pressure, improve moods in women with diabetes and depression

In women who have type 2 diabetes and show signs of depression, vitamin D supplements significantly lowered blood pressure and improved their moods, according to a pilot study at Loyola University Chicago Niehoff School of Nursing.

26 Jun 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

Patients are not at increased risk of Guillain-Barr- syndrome in the six-week period after vaccination with any vaccine, including influenza, according to a Kaiser Permanente study published in Clinical Infectious Diseases.

25 Jun 2013

IAIM seeks to support immunization managers to achieve vaccination goals

The Sabin Vaccine Institute today announced the launch of the newly-formed International Association of Immunization Managers (IAIM). With the support of a five-year grant from the Bill & Melinda Gates Foundation, IAIM's objective is to help drive the achievement of national, regional and international immunization goals, including those in the Global Vaccine Action Plan (GVAP), by fostering forward-thinking and superior management of immunization programs.

25 Jun 2013

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

Study finds U-shaped association between consumption of fish and risk of developing AF

Moderation seems to be key when it comes to eating fish to prevent atrial fibrillation according to an observational study presented at the EHRA EUROPACE congress held 23 to 26 June in Athens, Greece.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Administering large iron doses over short period of time increases patients' risk of infections

While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients' risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer.

24 Jun 2013

Pharmaceutical News

Supreme Court sides with generic drug makers

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

Report alerts clinicians, public about catastrophic dangers of contaminated epidural injections

Study explores analgesic activity of ceftriaxone in humans

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

Researchers discover promising new way to treat HIV-related blood cancer

Vitamin D supplements lower blood pressure, improve moods in women with diabetes and depression

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

IAIM seeks to support immunization managers to achieve vaccination goals

Study finds that triple therapy corrects two core defects in type 2 diabetes

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Study finds U-shaped association between consumption of fish and risk of developing AF

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Administering large iron doses over short period of time increases patients' risk of infections

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News